Variants in FIX propeptide associated with vitamin K antagonist hypersensitivity: functional analysis and additional data confirming the common founder mutations

Ann Hematol. 2018 Jun;97(6):1061-1069. doi: 10.1007/s00277-018-3264-2. Epub 2018 Feb 15.

Abstract

One of the most common and unwanted side effects during oral anticoagulant therapy (OAT) is bleeding complications. In rare cases, vitamin K antagonist (VKA)-related bleeding events are associated with mutations affecting the F9 propeptide at amino acid position 37 due to a substitution of alanine to either valine or threonine. Based on our actual cohort of 18 patients, we update the knowledge on this rare phenotype and its origin. A founder mutation for both variants was reconfirmed by haplotype analysis of intronic and extragenic short tandem repeat (STR) polymorphisms with a higher prevalence in Switzerland than in other regions of Europe. Screening of healthy individuals for the presence of these F9 gene mutations did not identify any of these variants, thus proving the rare occurrence of this genotype. Furthermore, both variants were expressed in vitro and warfarin dose responses were studied. Our warfarin dose response analysis confirmed higher sensitivity of both variants to warfarin with the effect being more apparent for Ala37Thr. Thus, although F9 propeptide mutation-associated hypersensitivity to VKA is a rare phenomenon, awareness towards this bleeding phenotype is important to identify patients at risk.

Keywords: F9 Thr37; F9 Val37; FIX; Hypersensitivity to VKA; Propeptide.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Amino Acid Substitution
  • Anticoagulants / adverse effects
  • Anticoagulants / pharmacology*
  • Cohort Studies
  • Factor IX / analysis
  • Factor IX / genetics*
  • Factor IX / metabolism
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • HEK293 Cells
  • Hemorrhage / blood
  • Hemorrhage / chemically induced
  • Hemorrhage / genetics
  • Hemorrhage / metabolism
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Polymorphism, Genetic*
  • Protein Interaction Domains and Motifs
  • Recombinant Proteins / metabolism
  • Switzerland
  • Tandem Repeat Sequences
  • Vitamin K / antagonists & inhibitors*
  • Warfarin / adverse effects
  • Warfarin / pharmacology

Substances

  • Anticoagulants
  • Recombinant Proteins
  • Vitamin K
  • Warfarin
  • Factor IX